Comparison

BPC-157 vs. TB-500

Two peptides side-by-side — identity, evidence base, legal status and known adverse events.

Identity

Mechanism of action

BPC-157

Synthetic peptide derived from a sequence of a protein found in gastric juice. In preclinical models, an influence on angiogenic and tissue-protective signalling pathways has been described. The precise molecular mechanisms of action are not conclusively understood.

TB-500

Synthetic fragment of the endogenous protein Thymosin Beta-4. In preclinical models, an influence on cell migration, actin sequestration and neovascularisation has been described. Robust human pharmacokinetic data are not publicly available.

Evidence base

Highest evidence

Animal model

Studies

of which in humans

Effects recorded

Open conflicts

Documented adverse events

Legal status

Country	BPC-157	TB-500
Australia	Banned	Banned
Switzerland	Unapproved	—
Germany	Unapproved	Unapproved
United States	Research only	Research only

Full entries

Frequently asked questions

What is the difference between BPC-157 and TB-500?: BPC-157 is classified as "Healing", while TB-500 is classified as "Healing". BPC-157: Synthetic pentadecapeptide (15 amino acids) derived from a sequence of a gastric-juice protein. Studied predominantly in animal models on healing and protective processes — controlled human trials are rare and limited in scope. TB-500: Synthetic fragment of the endogenous protein Thymosin Beta-4, specifically the actin-binding sequence. Preclinical models investigate effects on cell migration, neovascularisation and wound healing — robust human data are absent. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, BPC-157 or TB-500?: The highest available evidence level is "Animal model" for BPC-157 and "Animal model" for TB-500. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of BPC-157 and TB-500 in Germany and the United States?: Germany: BPC-157 — Unapproved, TB-500 — Unapproved. United States: BPC-157 — Research only, TB-500 — Research only. These are factual summaries with source and review date on the individual pages.

Country

BPC-157

TB-500

Australia

Banned

Switzerland

Unapproved

—

Germany

Unapproved

United States

Research only

Frequently asked questions

What is the difference between BPC-157 and TB-500?

BPC-157 is classified as "Healing", while TB-500 is classified as "Healing". BPC-157: Synthetic pentadecapeptide (15 amino acids) derived from a sequence of a gastric-juice protein. Studied predominantly in animal models on healing and protective processes — controlled human trials are rare and limited in scope. TB-500: Synthetic fragment of the endogenous protein Thymosin Beta-4, specifically the actin-binding sequence. Preclinical models investigate effects on cell migration, neovascularisation and wound healing — robust human data are absent. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, BPC-157 or TB-500?

The highest available evidence level is "Animal model" for BPC-157 and "Animal model" for TB-500. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of BPC-157 and TB-500 in Germany and the United States?

Germany: BPC-157 — Unapproved, TB-500 — Unapproved. United States: BPC-157 — Research only, TB-500 — Research only. These are factual summaries with source and review date on the individual pages.